To explore the potential link between glycosylation patterns on tumor cells (CLR-ligands) and immune modulations, we assessed the tumor glyco-code by performing lectin arrays (GLYcoPROFILETM technology) of primary tumor cell lines derived from melanoma patients (n=23) using human adult melanocytes as control (n=2 to 6) (Figure 2A). This evidence concerns the gene DCLK3 and neoplasm.